Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022

RT @SuffolkCoHealth: In this study, bivalent mRNA boosters provided significant protection against symptomatic SARS-CoV-2 infection in pers…

RT @ArielCohen37: New CDC data shows the updated COVID-19 booster shots is about 50% more effective at preventing symptomatic infection com…

@apoorva_nyc @celinegounder https://t.co/bsdvN6qDkw

New data from CDC on effectiveness of bivalent (BA.4/5) mRNA Covid vaccines. Efficacy against symptomatic infection is ~30% relative to people who had the last of their two or more doses of the original 2-3 months earlier https://t.co/0CCgG5ulJy

RT @Alexander_Tin: New in @CDCMMWR: our first look at effectiveness of updated bivalent boosters relative to 2 monovalent shots against s…

RT @Alexander_Tin: New in @CDCMMWR: our first look at effectiveness of updated bivalent boosters relative to 2 monovalent shots against s…

RT @W7VOA: Here's the study Dr. Fauci just referenced during his likely final appearance in the @WhiteHouse briefing room. https://t.co/bWG…

RT @DoctorTro: The media arm of Pfizer is advertising another retrospective review https://t.co/HeSlZQcnfS

RT @W7VOA: Here's the study Dr. Fauci just referenced during his likely final appearance in the @WhiteHouse briefing room. https://t.co/bWG…

@RNAiAnalyst that chart is cut and pasted from CDC's report https://t.co/cQXqqIiazP

Real world Effectiveness study and Quote: "In this study of vaccine effectiveness of the U.S.-authorized bivalent mRNA booster formulations, bivalent boosters provided significant additional protection against symptomatic SARS-CoV-2 infection..." https://

RT @cmsub: (New CDC data showing an updated bivalent booster provides additional protection against symptomatic infection compared w/ 2 dos…

https://t.co/3GPp5cJFtZ

shoutout all boosted bois we out here

RT @ArielCohen37: New CDC data shows the updated COVID-19 booster shots is about 50% more effective at preventing symptomatic infection com…

RT @ArielCohen37: New CDC data shows the updated COVID-19 booster shots is about 50% more effective at preventing symptomatic infection com…

RT @Alexander_Tin: New in @CDCMMWR: our first look at effectiveness of updated bivalent boosters relative to 2 monovalent shots against s…

RT @W7VOA: Here's the study Dr. Fauci just referenced during his likely final appearance in the @WhiteHouse briefing room. https://t.co/bWG…

RT @josephsreed: Go get the new shots!

RT @ArielCohen37: New CDC data shows the updated COVID-19 booster shots is about 50% more effective at preventing symptomatic infection com…

RT @cmsub: (New CDC data showing an updated bivalent booster provides additional protection against symptomatic infection compared w/ 2 dos…

RT @DocJeffD: "...bivalent mRNA booster formulations, bivalent boosters provided significant additional protection against symptomatic SARS…

RT @Alexander_Tin: New in @CDCMMWR: our first look at effectiveness of updated bivalent boosters relative to 2 monovalent shots against s…

RT @Alexander_Tin: New in @CDCMMWR: our first look at effectiveness of updated bivalent boosters relative to 2 monovalent shots against s…

RT @Alexander_Tin: New in @CDCMMWR: our first look at effectiveness of updated bivalent boosters relative to 2 monovalent shots against s…

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022. MMWR Morb Mortal Wkly Rep. ePub: 22 November 2022. DOI: https://t.co/gTPZPyEizv

(New CDC data showing an updated bivalent booster provides additional protection against symptomatic infection compared w/ 2 doses of the original vaccine) https://t.co/bnnVxKHizi

"...bivalent mRNA booster formulations, bivalent boosters provided significant additional protection against symptomatic SARS-CoV-2 infection in persons who had previously received 2, 3, or 4 monovalent vaccine doses." Get your updated booster. https://t

"Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection..." #COVID19 CDC https://t.co/VPKThOLAOz

RT @ArielCohen37: New CDC data shows the updated COVID-19 booster shots is about 50% more effective at preventing symptomatic infection com…

RT @ArielCohen37: New CDC data shows the updated COVID-19 booster shots is about 50% more effective at preventing symptomatic infection com…

It’s good to see clinical efficacy numbers on the bivalent boosters. A few points—better to wait 8 months or so post last vaccination in low risk individuals; this is early efficacy so unclear how long will last; how durable against the BA4/5 descendants?

RT @Alexander_Tin: New in @CDCMMWR: our first look at effectiveness of updated bivalent boosters relative to 2 monovalent shots against s…

Go get the new shots!

RT @ArielCohen37: New CDC data shows the updated COVID-19 booster shots is about 50% more effective at preventing symptomatic infection com…

Here's the study Dr. Fauci just referenced during his likely final appearance in the @WhiteHouse briefing room. https://t.co/bWGiEzPGid

In this study, bivalent mRNA boosters provided significant protection against symptomatic SARS-CoV-2 infection in persons who received 2, 3, or 4 monovalent vaccine doses. The benefit increased with time since receipt of the most recent monovalent dose. ht

New CDC data shows the updated COVID-19 booster shots is about 50% more effective at preventing symptomatic infection compared 2 doses of the original shot. https://t.co/6zZ7boukks

EARLY RELEASE: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing … https://t.co/daeT17A5ZW https://t.co/f9rp8QX9jc

Ok another not very useful study but better than nothing. The bivalent BA5 booster had produced *some* protection against BA5 symptomatic infection in people with waned prior vax. Summary: Elderly might benefit during the winter wave. 💝

The media arm of Pfizer is advertising another retrospective review https://t.co/HeSlZQcnfS

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 Early Release / November 22, 2022 / 71 via #MMWR Center…https://t.co/pWhHHvHsnG

New in @CDCMMWR: our first look at effectiveness of updated bivalent boosters relative to 2 monovalent shots against symptomatic COVID, from @CDCgov's ICATT Among those w/ last shot ≥8 months ago: 56% in 18–49 yrs 48% in 50–64 yrs 43% in ≥65 yrs https